BioSpectrum
the business of Bio & Health Sciences
ASIA EDITION

BioVersys announces first subjects dosed in Ph 1 clinical trial of BV100

November 18, 2020 | News

BV100 is a potential breakthrough hospital antibiotic to treat serious infections caused by Carbapenem Resistant Acinetobacter baumannii



Switzerland based Bioversys has recently reached a major milestone by entering clinical development with the start of Phase 1 testing of BV100 in healthy volunteers. BioVersys AG, a privately owned, multi-asset Swiss pharmaceutical company focused on developing small molecules for multidrug-resistant bacterial infections with applications in Anti-Microbial Resistance (AMR) and targeted microbiome modulation, today announced that the first healthy volunteers have received BV100 in Phase 1 clinical trial designed to evaluate the safety, tolerability, and pharmacokinetics of BV100 in healthy human volunteers through Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) studies.

- BV100 is a potential breakthrough hospital antibiotic to treat serious infections caused by Carbapenem Resistant *Acinetobacter baumannii*(CRAB) in indications of ventilator-associated bacterial pneumonia (VABP), hospital-acquired bacterial pneumonia (HABP) and bloodstream infections (BSI), for which there are little to no effective and safe treatment options. BioVersys has developed a proprietary human IV formulation of BV100 for the CRAB hospital market and elucidated the unique mode of action that accounts for its tremendous potency and coverage of clinical CRAB isolates.
- BV100 has completed GLP toxicology studies and has shown outstanding in vitro and in vivo efficacy in several animal models, with unprecedented in vitro strain coverage against CRAB and a very low propensity to develop resistance.